KR20010032320A - 용해된 파록세틴을 포함하는 제형 - Google Patents

용해된 파록세틴을 포함하는 제형 Download PDF

Info

Publication number
KR20010032320A
KR20010032320A KR1020007005532A KR20007005532A KR20010032320A KR 20010032320 A KR20010032320 A KR 20010032320A KR 1020007005532 A KR1020007005532 A KR 1020007005532A KR 20007005532 A KR20007005532 A KR 20007005532A KR 20010032320 A KR20010032320 A KR 20010032320A
Authority
KR
South Korea
Prior art keywords
paroxetine
capsule
carrier
solid
solid dosage
Prior art date
Application number
KR1020007005532A
Other languages
English (en)
Korean (ko)
Inventor
아마드 가자위
그레이엄 스탠리 레너드
Original Assignee
피터 기딩스
스미스클라인비이참피이엘시이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 기딩스, 스미스클라인비이참피이엘시이 filed Critical 피터 기딩스
Publication of KR20010032320A publication Critical patent/KR20010032320A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020007005532A 1997-11-21 1998-11-18 용해된 파록세틴을 포함하는 제형 KR20010032320A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9724544.3A GB9724544D0 (en) 1997-11-21 1997-11-21 Novel Formulation
GB9724544.3 1997-11-21
PCT/GB1998/003471 WO1999026625A1 (en) 1997-11-21 1998-11-18 Formulations comprising dissolved paroxetine

Publications (1)

Publication Number Publication Date
KR20010032320A true KR20010032320A (ko) 2001-04-16

Family

ID=10822374

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007005532A KR20010032320A (ko) 1997-11-21 1998-11-18 용해된 파록세틴을 포함하는 제형

Country Status (24)

Country Link
EP (1) EP1033986A1 (es)
JP (1) JP2001523718A (es)
KR (1) KR20010032320A (es)
CN (1) CN1279608A (es)
AP (1) AP2000001821A0 (es)
AR (1) AR015485A1 (es)
AU (1) AU1168099A (es)
BG (1) BG104527A (es)
BR (1) BR9814220A (es)
CO (1) CO4970832A1 (es)
DZ (1) DZ2658A1 (es)
EA (1) EA200000552A1 (es)
GB (1) GB9724544D0 (es)
HU (1) HUP0100580A3 (es)
IL (1) IL136106A0 (es)
MA (1) MA24704A1 (es)
NO (1) NO20002590L (es)
OA (1) OA11385A (es)
PE (1) PE20000381A1 (es)
PL (1) PL340555A1 (es)
SK (1) SK7342000A3 (es)
TR (1) TR200001423T2 (es)
WO (1) WO1999026625A1 (es)
ZA (1) ZA9810637B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810180D0 (en) * 1998-05-13 1998-07-08 Smithkline Beecham Plc Novel formulation
CA2367402C (en) * 1999-03-12 2010-11-23 Basf Aktiengesellschaft Stable pharmaceutical dosage form for paroxetine anhydrate
WO2001002393A1 (en) 1999-07-01 2001-01-11 Italfarmaco S.P.A. Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives
DE19930454A1 (de) * 1999-07-02 2001-01-04 Knoll Ag Feste Paroxetin enthaltende Zubereitungen
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
ES2294197T3 (es) * 2001-12-21 2008-04-01 Supernus Pharmaceuticals, Inc. Formulacion de capsula oral con estabilidad fisica aumentada.
SE0200475D0 (sv) * 2002-02-15 2002-02-15 Ltp Lipid Technologies Provide Oral farmaceutisk beredning
WO2006119779A2 (en) * 2005-05-10 2006-11-16 Lifecycle Pharma A/S A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution
US20120322752A1 (en) * 2009-12-08 2012-12-20 Sung Kyun Lee SOLID DISPERSIONS CONTAINING 20-O-beta-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031197A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
HUP0000960A3 (en) * 1997-01-15 2001-04-28 Smithkline Beecham Plc Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
BG104527A (en) 2001-04-30
AU1168099A (en) 1999-06-15
OA11385A (en) 2004-01-27
MA24704A1 (fr) 1999-07-01
ZA9810637B (en) 2000-05-22
DZ2658A1 (fr) 2003-03-22
BR9814220A (pt) 2001-12-26
EP1033986A1 (en) 2000-09-13
HUP0100580A2 (hu) 2002-04-29
NO20002590D0 (no) 2000-05-19
PL340555A1 (en) 2001-02-12
PE20000381A1 (es) 2000-05-07
NO20002590L (no) 2000-07-19
EA200000552A1 (ru) 2000-10-30
TR200001423T2 (tr) 2000-10-23
JP2001523718A (ja) 2001-11-27
SK7342000A3 (en) 2000-12-11
CN1279608A (zh) 2001-01-10
CO4970832A1 (es) 2000-11-07
IL136106A0 (en) 2001-05-20
WO1999026625A1 (en) 1999-06-03
HUP0100580A3 (en) 2002-05-28
GB9724544D0 (en) 1998-01-21
AR015485A1 (es) 2001-05-02
AP2000001821A0 (en) 2000-06-30

Similar Documents

Publication Publication Date Title
US6524615B2 (en) Controlled release pharmaceutical composition
Panigrahi et al. Gelucire: A versatile polymer for modified release drug delivery system
US8293270B2 (en) Lipophilic vehicle-based dual controlled release matrix system
RU2278657C2 (ru) Предконцентрат микроэмульсии
AU2006311818B9 (en) Improved delivery of tetrahydrocannabinol
US6491950B1 (en) Controlled release pharmaceutical composition
BR112021001345A2 (pt) formulações multiparticuladas de canabinoides
US20140357708A1 (en) Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
WO2016022936A1 (en) An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
JP2001523705A (ja) 液晶構造体を利用する薬剤送達システム
MX2007012124A (es) Formulaciones mejoradas de fenofibrato.
AU2016203127B2 (en) An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
AU2019329905B2 (en) Vitamin D pediatric dosage forms, methods of making and using
CN1543359A (zh) 可生物利用的口服剂型醋氯芬酸组合物及其制备方法
KR20010032320A (ko) 용해된 파록세틴을 포함하는 제형
AU2013213706B2 (en) An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
KR100679582B1 (ko) 경질 쉘 캡슐용 이부프로펜 용액
US20020032220A1 (en) Formulations comprising dissolved paroxetine
JP2003504392A (ja) 新規医薬製剤
CA2310407A1 (en) Formulations comprising dissolved paroxetine
MXPA00005030A (es) Formulaciones que contienen paroxetina disuelta
CZ20001876A3 (cs) Prostředky obsahující rozpuštěný paroxetin

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid